Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fischer, Laura
NCT02134301 / 2013-005415-26: Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections	Recruiting	1	52	US	Oritavancin	Melinta Therapeutics, LLC	Gram Positive Bacterial Infections	12/24	06/25
TANGOKIDS, NCT02687906 / 2016-000656-99: Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections	Recruiting	1	67	US	Vabomere, Combination meropenem and vaborbactam, carbapenem and beta-lactamase inhibitor	Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC), Department of Health and Human Services	Bacterial Infections	12/24	06/25
PROJECTION, NCT04246203: Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer	Recruiting	N/A	200	Europe	Liquid Biopsy	Ludwig-Maximilians - University of Munich, Hoffmann-La Roche	Pancreas Cancer	12/24	12/25